Skip to main content
main-content

31.07.2018 | Melanomas | Ausgabe 11/2018 Open Access

Annals of Surgical Oncology 11/2018

Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study

Zeitschrift:
Annals of Surgical Oncology > Ausgabe 11/2018
Autoren:
MBBS, DipHR, MClinEd, MRCS, FHEA Ryckie G. Wade, MRes Alyss V. Robinson, BSc(Hons), MBChB, MRCS Michelle C. I. Lo, BSc, MSc, GradStat, PhD Claire Keeble, BM, BCh, MA, FRCP, PhD Maria Marples, BA, MBBS, MRCS(Eng), FRCS(Plast) Donald J. Dewar, MD, FRCS(Plast) Marc D. S. Moncrieff, MBChB, BSc, FRCS(Plast) Howard Peach
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1245/​s10434-018-6660-x) contains supplementary material, which is available to authorized users.
Presented at the triennial World Melanoma Congress, Brisbane, Australia, 2017; the Canadian Society of Surgical Oncology Annual Symposium, Vancouver Island, Canada, 2017, winning first-place prize; the British Association of Plastic, Reconstructive and Aesthetic Surgeons Winter Meeting, London, UK, 2017; the International Pigmented Cell International Congress, Denver, CO, USA, 2017; and the European Association of Dermato-Oncology International Congress, Athens, Greece, 2017.

Abstract

Background

In the peripheral blood, the neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) change in response to malignancy. These biomarkers are associated with adverse outcomes in numerous cancers, but the evidence is limited in relation to melanoma. This study sought to investigate the association between these biomarkers and survival in Stages I–III cutaneous melanoma.

Methods

This multicenter cohort study investigated a consecutive series of patients who underwent wide excision of biopsy-proven cutaneous melanoma and sentinel lymph node biopsy during a 10-year period. The baseline NLR and PLR were calculated immediately before sentinel lymph node biopsy. Adjusted hazard ratios (HRs) for overall and melanoma-specific survival were generated.

Results

Overall, 1351 patients were included in the study. During surveillance, 184 of these patients died (14%), with 141 of the deaths (77%) attributable to melanoma. Worse overall survival was associated with a baseline NLR lower than 2.5 [HR 2.2; 95% confidence interval (CI) 2.0 to 2.3; p < 0.001] and a baseline PLR lower than 100 (HR 1.8; 95% CI 1.7 to 1.8; p < 0.001). Melanoma-specific survival also was worse, with a baseline NLR lower than 2.5 (HR 1.9; 95% CI 1.6 to 2.2; p < 0.001) and a baseline PLR lower than 100 (HR 1.9; 95% CI 1.7 to 2.2; p < 0.001). The 5-year survival for patients with sentinel lymph node metastases and a low NLR and PLR was approximately 50%.

Conclusion

This study provides important new data on biomarkers in early-stage melanoma, which contrast with biomarker profiles in advanced disease. These biomarkers may represent the host inflammatory response to melanoma and therefore could help select patients for adjuvant therapy and enhanced surveillance.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Bis zum 22.10. bestellen und 100 € sparen!

e.Med Chirurgie

Kombi-Abonnement

Mit e.Med Chirurgie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Chirurgie, den Premium-Inhalten der chirurgischen Fachzeitschriften, inklusive einer gedruckten chirurgischen Zeitschrift Ihrer Wahl.

Nicht verpassen: e.Med bis 22. Oktober 100 € günstiger.

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Nicht verpassen: e.Med bis 22. Oktober 100 € günstiger.

Zusatzmaterial
Supplementary material 1 (DOCX 20 kb)
10434_2018_6660_MOESM1_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 11/2018

Annals of Surgical Oncology 11/2018Zur Ausgabe

Neu im Fachgebiet Chirurgie

 

 

 
 

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise